Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety and effectiveness of MBX-102 compared to
placebo when given orally once daily for 4 weeks for the treatment of hyperuricemia in
patients with gout.